Author:
Abdelmalek Manal,Choi Jaeduk,Kim Youngmin,Seo Kyounghee,Hompesch Marcus,Baek Seungjae
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. NASH drug treatment development: challenges and lessons;The Lancet Gastroenterology & Hepatology;2023-10
2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA;The Lancet;2023-08
3. A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis – Study design and rationale of HM-TRIA-201 study;Contemporary Clinical Trials;2023-07
4. The molecular pharmacology of glucagon agonists in diabetes and obesity;Peptides;2023-07
5. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease;The Lancet Gastroenterology & Hepatology;2023-02